Browse

Novo Nordisk’s attempt to dismiss a lawsuit about its CagriSema readout has failed, with the judge ruling that parts of the investors’ argument were strong enough for the case to proceed.

Processa Pharmaceuticals has made a push into the autoimmune space via the acquisition of Vidya Therapeutics, which delivers a potential rival to Novartis’ Rhapsido.

Caldera Therapeutics has struck a reverse merger with the publicly traded Synlogic and inked a $278 million financing deal, continuing the meteoric rise of the inflammatory bowel disease startup.